Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...170171172173174175176177178179180...208209»
  • ||||||||||  SHR-1501 / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date, Metastases:  A Study of SHR-1501 in Patients With Advanced Tumors (clinicaltrials.gov) -  Jul 22, 2020   
    P1,  N=48, Recruiting, 
    Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2020
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date:  A Trial of SHR3162 in Healthy Caucasian Volunteers (clinicaltrials.gov) -  Jul 21, 2020   
    P1,  N=12, Completed, 
    Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2020 Not yet recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2020
  • ||||||||||  Zynyz (retifanlimab-dlwr) / Incyte, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Reolysin (pelareorep) / Oncolytics, Andrus Reo
    Enrollment open, IO biomarker:  INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (clinicaltrials.gov) -  Jul 21, 2020   
    P2,  N=25, Recruiting, 
    Not yet recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2020 Not yet recruiting --> Recruiting
  • ||||||||||  oxaliplatin / Generic mfg., AiRuiKa (camrelizumab) / Incyte, capecitabine / Generic mfg.
    [VIRTUAL] Changes in immune function and prognosis in advanced perihilar cholangiocarcinoma patients treated with immunotherapy combined with different topical therapies (On-Demand) -  Jul 21, 2020 - Abstract #ESMO2020ESMO_424;    
    Cohort A: 125I particle stent + HAI + camrelizumab; Cohort B: 125I particle stent + camrelizumab; Cohort C: HAI + camrelizumab...HAI plan: HAI consisted of infusions of oxaliplatin 40 mg/ m2 for 2 hours, followed by 5-fluorouracil 800 mg/m2 for 22 hours on days 1∼3 every 3 weeks, a maximum of 6 cycles of HAI are applied for tumor control patients followed by maintenance with oral capecitabine until tumor progression...Secondary endpoints includes progress free survival (PFS), near-term outcome indicators (TBIL/DBIL/AST/ALT/ CEA/CA199 etc.), long-term outcome indicators (stent patency rate/ tumour response rate etc.), complications (fever/ bleeding/pain etc.), changes in immune-inflammatory cytokines (TNF-α/IL-1β/IL-6/ IL-8/CD4/CD8/IgA/IgG/IgM/complement C3 and C4), etc. Legal entity responsible for the study: The authors. Funding: Has not received any funding.
  • ||||||||||  AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change, Trial completion date:  A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer (clinicaltrials.gov) -  Jul 21, 2020   
    P1,  N=33, Completed, 
    Our clinical observations demonstrated that pyrotinib may be an effective treatment for patients with HER2-positive MBC. Active, not recruiting --> Completed | N=51 --> 33 | Trial completion date: Feb 2020 --> Jun 2020
  • ||||||||||  SHR-1703 / Jiangsu Hengrui Pharma
    New P1 trial:  A Trial of SHR-1703 in Healthy Adults (clinicaltrials.gov) -  Jul 20, 2020   
    P1,  N=42, Not yet recruiting, 
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Keytruda (pembrolizumab) / Merck (MSD)
    Trial termination, Metastases:  APPEASE: Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (clinicaltrials.gov) -  Jul 15, 2020   
    P1/2,  N=5, Terminated, 
    Apatinib single-agent use might be an effective and tolerable choice as salvage therapy for patients with recurrent or refractory cervical cancer. Active, not recruiting --> Terminated; Funding source withdrew financial support prior to start of Phase II portion of study
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Trial completion date, Trial primary completion date:  Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC (clinicaltrials.gov) -  Jul 13, 2020   
    P2,  N=90, Recruiting, 
    Active, not recruiting --> Terminated; Funding source withdrew financial support prior to start of Phase II portion of study Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2020 --> Jul 2021
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, irinotecan / Generic mfg.
    P2 data, Journal:  A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer. (Pubmed Central) -  Jul 10, 2020   
    Apatinib monotherapy showed promising efficiency for patients with refractory colorectal cancer, especially in patients with PS 0-1 or no liver metastasis. ctDNA abundance may be a predictor in serial monitoring of tumor load.
  • ||||||||||  SHR0410 / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change:  A Trial of SHR0410 Injection in Hemodialysis Participants. (clinicaltrials.gov) -  Jul 10, 2020   
    P1,  N=8, Completed, 
    Apatinib plus docetaxel is an effective and tolerable treatment option for advanced non-squamous NSCLC with wild-type EGFR. Recruiting --> Completed | N=24 --> 8
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date:  Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer (clinicaltrials.gov) -  Jul 9, 2020   
    P2,  N=60, Active, not recruiting, 
    Recruiting --> Completed | N=24 --> 8 Recruiting --> Active, not recruiting | Trial completion date: Nov 2019 --> Nov 2021 | Trial primary completion date: Nov 2018 --> Nov 2019
  • ||||||||||  plinabulin (BPI 2358) / BeyondSpring
    Trial completion date, Trial primary completion date:  DUBLIN-3: Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (clinicaltrials.gov) -  Jul 9, 2020   
    P3,  N=554, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Nov 2019 --> Nov 2021 | Trial primary completion date: Nov 2018 --> Nov 2019 Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: May 2020 --> Nov 2020
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  APPEASE: Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (clinicaltrials.gov) -  Jul 9, 2020   
    P1/2,  N=5, Active, not recruiting, 
    Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: May 2020 --> Nov 2020 N=119 --> 5 | Trial completion date: Jun 2023 --> Aug 2020 | Trial primary completion date: Jun 2023 --> Aug 2019
  • ||||||||||  plinabulin (BPI 2358) / BeyondSpring
    Enrollment closed, Trial completion date, Trial primary completion date:  PROTECTIVE-2: Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia (clinicaltrials.gov) -  Jul 9, 2020   
    P3,  N=222, Active, not recruiting, 
    N=119 --> 5 | Trial completion date: Jun 2023 --> Aug 2020 | Trial primary completion date: Jun 2023 --> Aug 2019 Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Oct 2020
  • ||||||||||  plinabulin (BPI 2358) / BeyondSpring
    Enrollment closed, Trial completion date, Trial primary completion date:  Protective-1: Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (clinicaltrials.gov) -  Jul 9, 2020   
    P3,  N=190, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Oct 2020 Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Oct 2020